Rezolute (NASDAQ:RZLT – Get Free Report) released its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports.
Rezolute Stock Down 1.0%
NASDAQ RZLT opened at $3.90 on Friday. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46. The business has a 50 day moving average price of $4.58 and a 200-day moving average price of $4.02. The company has a market cap of $375.53 million, a price-to-earnings ratio of -5.13 and a beta of 0.60.
Analyst Ratings Changes
Several analysts have recently commented on RZLT shares. BTIG Research raised their price objective on shares of Rezolute from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Guggenheim boosted their target price on shares of Rezolute from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, June 15th. HSBC raised shares of Rezolute to a “buy” rating in a research note on Friday. Citizens Jmp upgraded shares of Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price target for the company in a report on Wednesday, June 3rd. Finally, Wedbush lifted their price target on shares of Rezolute from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.00.
Rezolute Company Profile
Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.
Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.
Further Reading
- Five stocks we like better than Rezolute
- MarketBeat Week in Review – 09/21 – 09/25
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
